Skip to main content

Table 1 Clinical characteristics of the studied patients

From: Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

 

Treated (n = 32)

Controls (n = 26)

p

Gender (male %)

63%

50%

0.3

Age (yr)

63 ± 15

73 ± 12

0.02

Origin of sepsis

   

Abdominal

56%

42%

 

Bone

0%

4%

 

Respiratory

34%

27%

 

Skin/soft tissue

10%

23%

 

Urinary tract

0%

4%

 

SAPS II

56 ± 13

59 ± 11

0.4

APACHE II

25 ± 6

24 ± 7

0.6

SOFA score at inclusion

11 ± 3

11 ± 2

0.4

Value at inclusion

Mean arterial pressure (mmHg)

77 ± 9

75 ± 11

0.6

 

Norepinephrine dose (mcg/kg/min)

0.8 ± 1.0

0.4 ± 0.33

0.04

 

Heart rate (bpm)

94 ± 20

96 ± 22

0.7

 

Lactate (mmol/L)

3.5 ± 2.0

4.0 ± 3.5

0.6

 

pH

7.30 ± 0.11

7.31 ± 0.12

0.8

 

Base deficit (mmol/L)

−9.0 ± 4.3

−7.5 ± 7.2

0.4

 

ScvO2 (%)

70 ± 10

71 ± 13

0.8

 

SpO2 (%)

96 ± 4

98 ± 3

0.2

 

PaO2/FiO2

181 ± 102

255 ± 164

0.3

 

Hb (g/dL)

11.2 ± 2.0

10.9 ± 2.2

0.6

 

StO2 (%)

80 ± 8

78 ± 12

0.5

 

Deoxygenation slope (%/min)

−16.2 ± 18

−17.4 ± 14.4

0.4

 

Reoxygenation slope (%/s)

3.2 ± 2.6

2.3 ± 1.8

0.1

Mortality (n, %)

6 (19)

10 (38)

0.09

Length of ICU stay (days)

26 ± 21

19 ± 17

0.2

  1. Clinical characteristics at inclusion according to treatment group. Continuous variables are expressed as mean ± SD. Categorical variables are expressed as proportions (%). Two-tailed significance is shown under “p” column.